在放射学阳性中轴型脊柱关节炎患者中比较抗TNF治疗加用非甾体抗炎药与单用抗TNF治疗对脊柱结构损伤进展影响的2年随机对照CONSUL试验
CONSUL试验纳入具有放射学进展危险因素的放射学阳性中轴型脊柱关节炎患者,经戈利木单抗50 mg每4周12周导入期后,将临床应答良好者随机分为戈利木单抗联合塞来昔布200 mg每日两次组或戈利木单抗单药组,随访至第108周。结果显示联合治疗在延缓脊柱放射学进展方面未显示统计学显著优于单药治疗,两组不良事件和严重不良事件无显著差异。
要点
- 第108周mSASSS变化单药组1.7(95%CI 0.8至2.6)vs联合组1.1(95%CI 0.4至1.8),p=0.79。
- 新发韧带骨赘单药组25% vs联合组11%,p=0.12。
- 两组不良事件和严重不良事件无显著差异。
核心结论
- 在放射学阳性中轴型脊柱关节炎患者中,戈利木单抗联合塞来昔布治疗与戈利木单抗单药治疗相比,在2年内延缓脊柱放射学进展方面未显示统计学显著优效性。
研究设计与样本
- 随机对照CONSUL试验:放射学阳性中轴型脊柱关节炎患者,具有放射学进展危险因素(高疾病活动度加C反应蛋白>5 mg/L和/或≥1个韧带骨赘),先接受戈利木单抗50 mg每4周12周导入期。
- 核心期96周内,仅第12周临床应答良好者按1:1随机分为戈利木单抗联合塞来昔布200 mg每日两次组或戈利木单抗单药组。
- 主要终点为意向治疗人群第108周改良Stoke强直性脊柱炎脊柱评分(mSASSS)变化。
主要发现
- 导入期纳入128例患者,第12周109例随机分为单药组(n=55)或联合组(n=54)。
- 第108周97例(单药组52例 vs 联合组45例)完成研究。
- 第108周mSASSS变化单药组1.7(95%CI 0.8至2.6)vs联合组1.1(95%CI 0.4至1.8),p=0.79。
- 新发韧带骨赘单药组25% vs联合组11%,p=0.12。
- 研究期间两组不良事件和严重不良事件无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The study aimed to evaluate the effect of adding a non-steroidal anti-inflammatory drug (NSAID), celecoxib (CEL), to a tumour necrosis factor inhibitor (TNFi), golimumab (GOL), compared with TNFi monotherapy on radiographic spinal progression in patients with radiographic axial spondyloarthritis (r-axSpA) over 2 years. METHODS: R-axSpA patients, having risk factors for radiographic progression (high disease activity plus C reactive protein >5 mg/L and/or ≥1 syndesmophyte(s)), underwent a 12-week run-in phase with GOL 50 mg every 4 weeks. In the core phase (96 weeks), only patients with a good clinical response at week 12 were randomised (1:1) to GOL+CEL 200 mg two times per day (combination therapy) or GOL monotherapy. The primary endpoint was radiographic progression assessed by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change at week 108 in the intent-to-treat population. RESULTS: A total of 128 patients were enrolled in the run-in phase; and 109 patients were randomised at week 12 to monotherapy (n=55) or combination therapy (n=54). At week 108, 97 (52 vs 45) patients completed the study. The change in mSASSS at week 108 was 1.7 (95% CI 0.8 to 2.6) in the monotherapy vs 1.1 (95% CI 0.4 to 1.8) in the combination therapy groups (p=0.79). New syndesmophytes occurred in 25% of patients in the monotherapy vs 11% of patients in the combination therapy groups (p=0.12). During the study, no significant differences in adverse events and serious adverse events were observed between the groups. CONCLUSIONS: Combination therapy with GOL+CEL did not demonstrate statistically significant superiority over GOL monotherapy in retarding radiographic spinal progression over 2 years in r-axSpA.
引用
- Proft F, Torgutalp M, Muche B, et al. Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial. Ann Rheum Dis. 2024. PMID: 38228361. doi:10.1136/ard-2023-224699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。